CRISPR technology is overcoming the limitations of CAR-T cell therapy and opening new horizons for next-generation cancer immunotherapy. Conventional CAR-T cell therapy, which involves genetically modifying a patient's T-cells ex vivo and then re-injecting them, has been successful in hematological cancers but has shown limited efficacy in solid tumors. However, recent studies are dramatically improving the efficacy of solid tumor treatment by using CRISPR to remove the PTPN2 gene or by developing CAR-T cells that target the Lewis Y antigen. On October 31, 2025, CRISPR Medicine News reported that researchers successfully enhanced the therapeutic potential of CAR-T cells by combining CRISPR-Cas9 with small molecule inhibitors. Additionally, CRISPR technology for correcting EGFR (epidermal growth factor receptor) exon 19 deletion mutations is being applied to the treatment of non-small cell lung cancer (NSCLC). Stanford Medicine is further accelerating gene editing speed by developing CRISPR-GPT, a large language model integrated with AI. CRISPR cancer treatment is leading the future of personalized medicine and entering the commercialization phase. In May 2025, Children's Hospital of Philadelphia (CHOP) unveiled the case of 'KJ,' the world's first patient to receive personalized CRISPR gene editing therapy. KJ received the first infusion in late February, followed by subsequent booster doses in March and later, making the potential of personalized gene therapy a reality. Intima Biosciences also announced results from a Phase 1/2 clinical trial using CRISPR-edited tumor-infiltrating lymphocytes in patients with metastatic colorectal cancer. Currently, several companies are pursuing FDA approval for CRISPR-based cancer therapies, with numerous Phase 3 clinical trial results expected to be announced from the second half of 2025 through 2026. CRISPR is no longer just a laboratory technology but is establishing itself as a practical treatment option offering new hope to patients.